Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis
Status:
Terminated
Trial end date:
2020-04-26
Target enrollment:
Participant gender:
Summary
Mechanical heart valves (MHV) demand lifelong anticoagulation with vitamin K antagonists
(VKA) due to the high thrombogenicity of the prosthesis. Rivaroxaban has previously been
tested in experimental and animal models with encouraging results. The investigators recently
sent for publication an experiment with 7 patients who used rivaroxaban in metallic
prosthesis with encouraging results. In this way it was decided to do a randomized
non-inferiority clinical trial comparing rivaroxaban with warfarin in patients with metallic
prosthesis.